References
- DaneseSFiocchiCUlcerative colitisN Engl J Med2011365181713172522047562
- SartorRBInnate immunity in the pathogenesis and therapy of IBDJ Gastroenterol200338Suppl 15S43S47
- RoglerGUpdate in inflammatory bowel disease pathogenesisCurr Opin Gastroenterol200420431131715703658
- LissnerDSiegmundBUlcerative colitis: current and future treatment strategiesDig Dis2013311919423797129
- RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353232462247616339095
- ReinischWSandbornWJRutgeertsPLong-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studiesInflamm Bowel Dis201218220121121484965
- ColombelJFRutgeertsPReinischWEarly mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitisGastroenterology201114141194120121723220
- SandbornWJRutgeertsPFeaganBGColectomy rate comparison after treatment of ulcerative colitis with placebo or infliximabGastroenterology2009137412501260 quiz 152019596014
- SandbornWJvan AsscheGReinischWAdalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitisGastroenterology20121422257265. e122062358
- KeystoneECGenoveseMCKlareskogLGO-FORWARD StudyGolimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnn Rheum Dis200968678979619066176
- SmolenJSKayJMattesonELInsights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior antitumour necrosis factor therapy: post-hoc analyses from the GO-AFTER studyAnn Rheum Dis2013
- SmolenJSKayJDoyleMKGO-AFTER study investigatorsGolimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialLancet2009374968521022119560810
- KavanaughAMcInnesIMeasePGolimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthritis Rheum200960497698619333944
- YangHKavanaughAAdverse effects of golimumab in the treatment of rheumatologic diseasesExpert Opin Drug Saf201413110311223984970
- SandbornWJFeaganBGMaranoCPURSUIT-SC Study GroupSubcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisGastroenterology20141461859523735746
- SandbornWJFeaganBGMaranoCPURSUIT-Maintenance Study GroupSubcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisGastroenterology2014146196109. e123770005
- FiehnCVaySInduction of inflammatory bowel disease flares by golimumab: report of three patients with enteropathic spondylarthritis or ankylosing spondylitis and comorbid colitisArthritis Rheum201163113640364121769847